Clinical Trials Logo

Clinical Trial Summary

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03013998
Study type Interventional
Source Beat AML, LLC
Contact Ashley Yocum, PhD
Phone 301-814-2788
Email ashley.yocum@lls.org
Status Recruiting
Phase Phase 1/Phase 2
Start date November 2016
Completion date December 2026